Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accounts Payables: 2010-2024

Historic Accounts Payables for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $211,000.

  • Altimmune's Accounts Payables rose 324.01% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 324.01%. This contributed to the annual value of $211,000 for FY2024, which is 89.81% down from last year.
  • Altimmune's Accounts Payables amounted to $211,000 in FY2024, which was down 89.81% from $2.1 million recorded in FY2023.
  • Altimmune's 5-year Accounts Payables high stood at $4.8 million for FY2022, and its period low was $211,000 during FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $2.1 million (2023), whereas its average is $2.4 million.
  • In the last 5 years, Altimmune's Accounts Payables skyrocketed by 3,258.34% in 2020 and then slumped by 89.81% in 2024.
  • Yearly analysis of 5 years shows Altimmune's Accounts Payables stood at $612,293 in 2020, then soared by 232.19% to $2.0 million in 2021, then skyrocketed by 136.18% to $4.8 million in 2022, then tumbled by 56.91% to $2.1 million in 2023, then tumbled by 89.81% to $211,000 in 2024.